1
|
Zhang X, Guan L, Zhu L, Wang K, Gao Y, Li J, Yan S, Ji N, Zhou Y, Yao X, Li B. A review of the extraction and purification methods, biological activities, and applications of active compounds in Acanthopanax senticosus. Front Nutr 2024; 11:1391601. [PMID: 38846546 PMCID: PMC11153764 DOI: 10.3389/fnut.2024.1391601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2024] [Accepted: 05/02/2024] [Indexed: 06/09/2024] Open
Abstract
Acanthopanax senticosus (AS) is a geo-authentic crude medicinal plant that grows in China, Korea, Russia, and Japan. AS contains bioactive compounds such as eleutherosides, polysaccharides, and flavonoids. It is also a key traditional herb in the Red List of Chinese Species. AS is mainly distributed in Northeast China, specifically in Heilongjiang, Jilin, and Liaoning provinces. Its active compounds contribute to significant biological activities, including neuroprotective, antioxidant, anti-fatigue, and antitumor effects. However, the extraction methods of active compounds are complex, the extraction efficiency is poor, and the structure-activity relationship is unclear. This study focused on the nutrients in AS, including protein, carbohydrates, and lipids. Particularly, the active ingredients (eleutherosides, polysaccharides, and flavonoids) in AS and their extraction and purification methods were analyzed and summarized. The biological activities of extracts have been reviewed, and the mechanisms of anti-oxidation, antitumor, anti-inflammation, and other activities are introduced in detail. The applications of AS in various domains, such as health foods, medicines, and animal dietary supplements, are then reported. Compared with other extraction methods, ultrasonic or microwave extraction improves efficiency, yet they can damage structures. Challenges arise in the recovery of solvents and in achieving extraction efficiency when using green solvents, such as deep eutectic solvents. Improvements can be made by combining extraction methods and controlling conditions (power, temperature, and time). Bioactive molecules and related activities are exposited clearly. The applications of AS have not been widely popularized, and the corresponding functions require further development.
Collapse
Affiliation(s)
- Xindi Zhang
- Food Processing Institute, Heilongjiang Academy of Agricultural Sciences, Harbin, China
- Key Laboratory of Food Processing of Heilongjiang Province, Harbin, China
| | - Lijun Guan
- Food Processing Institute, Heilongjiang Academy of Agricultural Sciences, Harbin, China
- Key Laboratory of Food Processing of Heilongjiang Province, Harbin, China
| | - Ling Zhu
- Food Processing Institute, Heilongjiang Academy of Agricultural Sciences, Harbin, China
- Key Laboratory of Food Processing of Heilongjiang Province, Harbin, China
| | - Kunlun Wang
- Food Processing Institute, Heilongjiang Academy of Agricultural Sciences, Harbin, China
- Key Laboratory of Food Processing of Heilongjiang Province, Harbin, China
| | - Yang Gao
- Food Processing Institute, Heilongjiang Academy of Agricultural Sciences, Harbin, China
- Key Laboratory of Food Processing of Heilongjiang Province, Harbin, China
| | - Jialei Li
- Food Processing Institute, Heilongjiang Academy of Agricultural Sciences, Harbin, China
- Key Laboratory of Food Processing of Heilongjiang Province, Harbin, China
| | - Song Yan
- Food Processing Institute, Heilongjiang Academy of Agricultural Sciences, Harbin, China
- Key Laboratory of Food Processing of Heilongjiang Province, Harbin, China
| | - Nina Ji
- Soybean Institute, Heilongjiang Academy of Agricultural Sciences, Harbin, China
| | - Ye Zhou
- Food Processing Institute, Heilongjiang Academy of Agricultural Sciences, Harbin, China
- Key Laboratory of Food Processing of Heilongjiang Province, Harbin, China
| | - Xinmiao Yao
- Food Processing Institute, Heilongjiang Academy of Agricultural Sciences, Harbin, China
- Key Laboratory of Food Processing of Heilongjiang Province, Harbin, China
| | - Bo Li
- Food Processing Institute, Heilongjiang Academy of Agricultural Sciences, Harbin, China
- Key Laboratory of Food Processing of Heilongjiang Province, Harbin, China
| |
Collapse
|
2
|
Ra SW, Sze MA, Lee EC, Tam S, Oh Y, Fishbane N, Criner GJ, Woodruff PG, Lazarus SC, Albert R, Connett JE, Han MK, Martinez FJ, Aaron SD, Reed RM, Man SFP, Sin DD. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. Respir Res 2017; 18:109. [PMID: 28558695 PMCID: PMC5450077 DOI: 10.1186/s12931-017-0594-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Accepted: 05/19/2017] [Indexed: 02/08/2023] Open
Abstract
BACKGROUND Helicobacter pylori (HP) infection is associated with reduced lung function and systemic inflammation in chronic obstructive pulmonary disease (COPD) patients. Azithromycin (AZ) is active against HP and reduces the risk of COPD exacerbation. We determined whether HP infection status modifies the effects of AZ in COPD patients. METHODS Plasma samples from 1018 subjects with COPD who participated in the Macrolide Azithromycin (MACRO) in COPD Study were used to determine the HP infection status at baseline and 12 months of follow-up using a serologic assay. Based on HP infection status and randomization to either AZ or placebo (PL), the subjects were divided into 4 groups: HP+/AZ, HP-/AZ, HP+/PL, and HP-/PL. Time to first exacerbation was compared across the 4 groups using Kaplan-Meier survival analysis and a Cox proportional hazards model. The rates of exacerbation were compared using both the Kruskal-Wallis test and negative binomial analysis. Blood biomarkers at enrolment and at follow-up visits 3, 12, and 13 (1 month after treatment was stopped) months were measured. RESULTS One hundred eighty one (17.8%) patients were seropositive to HP. Non-Caucasian participants were nearly three times more likely to be HP seropositive than Caucasian participants (37.4% vs 13.6%; p < 0.001). The median time to first exacerbation was significantly different across the four groups (p = 0.001) with the longest time in the HP+/AZ group (11.2 months, 95% CI; 8.4-12.5+) followed by the HP-/AZ group (8.0 months, 95% CI; 6.7-9.7). Hazard ratio (HR) for exacerbations was lowest in the HP+/AZ group after adjustment for age, sex, smoking status, ethnicity, history of peptic ulcer, dyspnea, previous hospital admission, GOLD grade of severity, and forced vital capacity (HR, 0.612; 95% CI, 0.442-0.846 vs HR, 0.789; 95% CI, 0.663-0.938 in the HP-/AZ group). Circulating levels of soluble tumor necrosis factor receptor-75 were reduced only in the HP+/AZ group after 3 months of AZ treatment (-0.87 ± 0.31 μg/L; p = 0.002); levels returned to baseline after discontinuing AZ. CONCLUSIONS AZ is effective in preventing COPD exacerbations in patients with HP seropositivity, possibly by modulating TNF pathways related to HP infection.
Collapse
Affiliation(s)
- Seung Won Ra
- Centre for Heart Lung Innovation, St. Paul's Hospital, & Department of Medicine (Respiratory Division), University of British Columbia, Don D Sin, Room 8446-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.,Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
| | - Marc A Sze
- Department of Microbiology & Immunology, University of Michigan, Ann Arbor, MI, USA
| | - Eun Chong Lee
- Centre for Heart Lung Innovation, St. Paul's Hospital, & Department of Medicine (Respiratory Division), University of British Columbia, Don D Sin, Room 8446-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada
| | - Sheena Tam
- Centre for Heart Lung Innovation, St. Paul's Hospital, & Department of Medicine (Respiratory Division), University of British Columbia, Don D Sin, Room 8446-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada
| | - Yeni Oh
- Centre for Heart Lung Innovation, St. Paul's Hospital, & Department of Medicine (Respiratory Division), University of British Columbia, Don D Sin, Room 8446-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada
| | - Nick Fishbane
- Centre for Heart Lung Innovation, St. Paul's Hospital, & Department of Medicine (Respiratory Division), University of British Columbia, Don D Sin, Room 8446-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada
| | - Gerard J Criner
- Department of Thoracic Medicine and Surgery, Temple University, Philadelphia, PA, USA
| | - Prescott G Woodruff
- Department of Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Stephen C Lazarus
- Department of Medicine, University of California San Francisco, San Francisco, CA, USA
| | - Richard Albert
- Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, CO, USA
| | - John E Connett
- School of Public Health, University of Minnesota, Minneapolis, MN, USA
| | - Meilan K Han
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
| | - Fernando J Martinez
- Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY, USA
| | - Shawn D Aaron
- Department of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Robert M Reed
- Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - S F Paul Man
- Centre for Heart Lung Innovation, St. Paul's Hospital, & Department of Medicine (Respiratory Division), University of British Columbia, Don D Sin, Room 8446-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada
| | - Don D Sin
- Centre for Heart Lung Innovation, St. Paul's Hospital, & Department of Medicine (Respiratory Division), University of British Columbia, Don D Sin, Room 8446-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
| | | |
Collapse
|
4
|
Laurent J, Mégraud F, Fléjou JF, Caekaert A, Barthélemy P. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2001; 15:1787-93. [PMID: 11683693 DOI: 10.1046/j.1365-2036.2001.01104.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
BACKGROUND Helicobacter pylori eradication rates in France after therapy with omeprazole, amoxicillin and clarithromycin are among the lowest in Europe. This study evaluated alternative eradication regimens. METHODS Helicobacter pylori-positive patients (n=323) with non-ulcer dyspepsia were randomized to receive one of four 1-week regimens consisting of omeprazole, 20 mg b.d., plus either: amoxicillin, 1000 mg b.d., and clarithromycin, 500 mg b.d. (OAC); bacampicillin, 1200 mg b.d., and clarithromycin, 500 mg b.d. (OBC); clarithromycin, 250 mg b.d., and metronidazole, 500 mg b.d. (OCM); or amoxicillin, 1000 mg b.d, and azithromycin, 500 mg on day 1 and 250 mg on days 2-5 (OAAz). Eradication was confirmed by urea breath test 4-6 weeks after treatment. Susceptibility testing was performed in the case of eradication failure. RESULTS The eradication rate with OAAz was 38% (95% CI, 25.6-49.4) on intention-to-treat analysis, which was lower (P < 0.05) than with the other regimens [OCM, 61% (50.0-72.8); OBC, 65% (54.0-76.5); OAC, 72% (61.8-81.8)]. Of the strains isolated following treatment failure with OAC, OBC or OCM, 84% were clarithromycin resistant. CONCLUSIONS OAC remains the reference treatment for H. pylori eradication in France, although bacampicillin offers a useful alternative to amoxicillin. Susceptibility testing should be considered after unsuccessful eradication therapy.
Collapse
Affiliation(s)
- J Laurent
- 127 rue Saint Dizier, Nancy, France.
| | | | | | | | | |
Collapse
|